Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DHPS | P49366 | 1/20 | 0.41 |
| ▸ | ADORA2A | P29274 | 7/20 | 0.39 |
| ▸ | ADORA1 | P30542 | 6/20 | 0.39 |
| ▸ | IDH1 | O75874 | 1/20 | 0.36 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 2/20 | 0.36 |
| ▸ | MGAM | O43451 | 1/20 | 0.36 |
| ▸ | SI | P14410 | 1/20 | 0.36 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.36 |
| ▸ | EGFR | P00533 | 1/20 | 0.36 |
| ▸ | TUBB4A | P04350 | 1/20 | 0.36 |
| ▸ | TUBB | P07437 | 1/20 | 0.36 |
| ▸ | TUBA3C | P0DPH7 | 1/20 | 0.36 |
| ▸ | TUBA1B | P68363 | 1/20 | 0.36 |
| ▸ | TUBA4A | P68366 | 1/20 | 0.36 |
| ▸ | TUBB4B | P68371 | 1/20 | 0.36 |
| ▸ | TUBB3 | Q13509 | 1/20 | 0.36 |
| ▸ | TUBB2A | Q13885 | 1/20 | 0.36 |
| ▸ | TUBB8 | Q3ZCM7 | 1/20 | 0.36 |
| ▸ | TUBA3E | Q6PEY2 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3872580 | 0.80 | ADORA1 (0.58) | ADORA2AADORA1NPC1RAB9A | |
| SCHEMBL4251648 | 0.77 | ADORA1 (0.46) | DHPSADORA2AADORA1EGFR | |
| SCHEMBL4251467 | 0.76 | ABL1 (0.43) | ADORA2AADORA1GAAMGAMSI | |
| SCHEMBL5256030 | 0.74 | DHPS (0.47) | DHPSADORA2AADORA1IDH1ADORA3 | |
| SCHEMBL4406463 | 0.72 | MGAM (0.45) | ADORA2AADORA1GAAMGAMSI | |
| SCHEMBL4258799 | 0.72 | ADORA2A (0.38) | ADORA2AADORA1ADORA3GAAMGAM | |
| SCHEMBL4251794 | 0.72 | KDM4E (0.39) | ADORA2AADORA1ADORA3PDK2NPC1 | |
| SCHEMBL18640917 | 0.71 | PDK2 (0.59) | ADORA2AADORA1GAAEGFRPDK2 | |
| SCHEMBL4257499 | 0.71 | ALDH1A1 (0.51) | ADORA2AADORA1NPC1SMN1; SMN2 | |
| SCHEMBL4256692 | 0.69 | ADORA2A (0.39) | ADORA2AADORA1ADORA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7598252-B2 | Compounds specific to adenosine A, receptors and uses thereof | OSI PHARMACEUTICALS, INC. (US) | 2009-10-06 | — | — | US | disclosed |
| US-20090082369-A1 | Pyrrolo[2,3d]pyrimidine compositions and their use | OSI PHARMACEUTICALS, INC. | 2009-03-26 | — | — | US | disclosed |
| EP-2011499-A2 | Pyrrolo[2,3d]Pyrimidine compositions and their use | OSI Pharmaceuticals, Inc. (US) | 2009-01-07 | — | — | EP | disclosed |
| US-7429574-B2 | 4-heterocyclo-pyrrolo[2,3d] pyrimidine compositions and their use | OSI PHARMACEUTICALS, INC. (US) | 2008-09-30 | — | — | US | disclosed |
| US-20080070936-A1 | Compounds specific to adenosine A1 receptors and uses thereof | OSI PHARMACEUTICALS, INC. | 2008-03-20 | — | — | US | disclosed |
| US-7160890-B2 | Compounds specific to adenosine A3 receptor and uses thereof | OSI PHARMACEUTICALS, INC. (US) | 2007-01-09 | — | — | US | disclosed |
| US-20050043332-A1 | Pyrrolo[2,3d]pyrimidine compositions and their use | OSI PHARMACEUTICALS, INC. | 2005-02-24 | — | — | US | disclosed |
| US-6800633-B2 | CARDIOVASCULAR DISORDERS; NERVOUS SYSTEM DISORDERS | OSI PHARMACEUTICALS, INC. | 2004-10-05 | — | — | US | disclosed |
| US-20040082598-A1 | Compounds specific to adenosine A, receptors and uses thereof | OSI PHARMACEUTICALS, INC. | 2004-04-29 | — | — | US | disclosed |
| US-20040082599-A1 | Compounds specific to adenosine A1 receptors and uses thereof | OSI PHARMACEUTICALS, INC. | 2004-04-29 | — | — | US | disclosed |
| US-6680322-B2 | FOR THERAPY OF ASTHMA, ALLERGIC RHINITIS, RESPIRATORY SYSTEM DISORDERS | OSI PHARMACEUTICALS, INC. | 2004-01-20 | — | — | US | disclosed |
| US-6680324-B2 | 4-AMINO-6-PHENYL-PYRROLO(2,3-D)PYRIMIDINE DERIVATIVES | OSI PHARMACEUTICALS, INC. | 2004-01-20 | — | — | US | disclosed |
| US-6673802-B2 | CARDIOVASCULAR DISORDERS; CENTRAL NERVOUS SYSTEM DISORDERS | OSI PHARMACEUTICALS, INC. | 2004-01-06 | — | — | US | disclosed |
| US-20030073708-A1 | Compounds specific to adenosine A3 receptor and uses thereof | OSI PHARMACEUTICALS, INC. | 2003-04-17 | — | — | US | disclosed |
| US-20030045536-A1 | Compounds specific to adenosine A1 receptors and uses thereof | OSI PHARMACEUTICALS, INC. | 2003-03-06 | — | — | US | disclosed |
| US-20020094974-A1 | Compounds specific to adenosine A3 receptor and uses thereof | OSI PHARMACEUTICALS, INC. | 2002-07-18 | — | — | US | disclosed |
| US-20020058667-A1 | Compounds specific to adenosine A1 receptors and uses thereof | OSI PHARMACEUTICALS, INC. | 2002-05-16 | — | — | US | disclosed |
| US-20020028782-A1 | Pyrrolo [2, 3d] pyrimidine compositions and their use | OSI PHARMACEUTICALS, INC. | 2002-03-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030073708-A1 | Compounds specific to adenosine A3 receptor and uses thereof | ADORA3, ADORA2A, ADORA1 | DHPS 1274/4885ADORA2A 2/4885ADORA1 3/4885 |
| US-20040082598-A1 | Compounds specific to adenosine A, receptors and uses thereof | ADORA2A, ADORA1, ADORA3 | DHPS 1034/4885ADORA2A 1/4885ADORA1 2/4885 |
| US-20020058667-A1 | Compounds specific to adenosine A1 receptors and uses thereof | ADORA1, ADORA2A, ADORA3 | DHPS 991/4885ADORA2A 2/4885ADORA1 1/4885 |
| US-20030045536-A1 | Compounds specific to adenosine A1 receptors and uses thereof | ADORA1, ADORA2A, ADORA3 | DHPS 991/4885ADORA2A 2/4885ADORA1 1/4885 |
| US-20090082369-A1 | Pyrrolo[2,3d]pyrimidine compositions and their use | ADORA3, ADORA2A, ADORA1 | DHPS 142/4885ADORA2A 2/4885ADORA1 3/4885 |
| US-20080070936-A1 | Compounds specific to adenosine A1 receptors and uses thereof | ADORA1, ADORA2A, ADORA3 | DHPS 843/4885ADORA2A 2/4885ADORA1 1/4885 |
| US-20050043332-A1 | Pyrrolo[2,3d]pyrimidine compositions and their use | TYMP, UMPS, ADORA3 | DHPS 87/4885ADORA2A 7/4885ADORA1 38/4885 |
| US-20020028782-A1 | Pyrrolo [2, 3d] pyrimidine compositions and their use | TYMP, UMPS, ADORA3 | DHPS 87/4885ADORA2A 7/4885ADORA1 38/4885 |
| US-20040082599-A1 | Compounds specific to adenosine A1 receptors and uses thereof | ADORA1, ADORA2A, ADORA3 | DHPS 991/4885ADORA2A 2/4885ADORA1 1/4885 |
| US-20020094974-A1 | Compounds specific to adenosine A3 receptor and uses thereof | ADORA3, ADORA2A, ADORA1 | DHPS 1274/4885ADORA2A 2/4885ADORA1 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.